Exploring the Potential for Risk Reduction and Right Heart Reverse Remodeling in PAH: A Focus on Upfront Combination Therapy

Join us for a live virtual symposium!

 

Wednesday, October 20, 2021
5:00 PM – 6:00 PM CT

 

PROGRAM OVERVIEW

Pulmonary arterial hypertension (PAH) is a rapidly progressive disease that is fatal when left untreated. It is characterized by pulmonary vasoconstriction and vascular remodeling, which in turn leads to increased pulmonary vascular resistance and arterial pressure, decreased cardiac output, and ultimately right heart failure. In recent years, standard of care treatment has moved away from sequential monotherapy to upfront combination therapy. To ensure that clinicians are well-equipped to provide optimal PAH management, this educational program will provide up-to-date information on clinical trial evidence regarding the efficacy and safety of combination (dual and triple) treatment strategies. Additionally, the program will also address the role of noninvasive testing (eg, echocardiography) in early diagnosis, assessment of treatment response, and disease monitoring, as well as the importance of multidisciplinary care throughout the course of care.

FACULTY

Vallerie V. McLaughlin, MD
Professor
Department of Internal Medicine
University of Michigan
Ann Arbor, Michigan

 

John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Director, Pulmonary Hypertension Comprehensive Care Center​
Medical Director, Cardiovascular Medical Unit​
University of Utah Hospital​
Faculty Director of Cardiology Education​
University of Utah School of Medicine​
Salt Lake City, Utah

TARGET AUDIENCE

This educational initiative has been designed for pulmonologists, cardiologists, and nurse practitioners, physician assistants, nurses, and other healthcare providers involved in the care of patients with PAH.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Understand the complexity of the pathophysiology of right ventricular (RV) remodeling secondary to PAH.
  • Discuss the value of multidisciplinary management to support early diagnosis, early treatment initiation, and management of comorbidities.
  • Summarize the evidence regarding the use of noninvasive tests to evaluate right heat structure and function and assess mortality risk and evaluate treatment response.
  • Demonstrate understanding of recent data regarding upfront triple combination therapy on right heart reverse remodeling and risk reduction in PAH.

REGISTRATION

There is no registration fee for participating in this activity. To register, click the registration buttons on this page or call Integrity Continuing Education, Inc. at 1-855-835-4004.

MEDIA

Internet

ACCREDITATION

Physician Continuing Education

 

Accreditation Statement
Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Vallerie McLaughlin, MD
Consultant: Acceleron, Aerovate, Altavant, Bayer, Caremark, Civi Biopharma, Corvista, Gossamer Bio, Jassen, Merck, United Therapeutics
University Grant Support: Acceleron, Jassen, Sonovie, United Therapeutics

John Ryan, MD, MB, BCh, BAO, MRCPI, FACC, FAHA
Speakers Bureau: Bayer, Janssen PH, United Therapeutics

The Integrity Continuing Education planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education.

SUPPORTER ACKNOWLEDGEMENT

The activity has been supported by an educational grant by Actelion Pharmaceuticals US Inc., a Janssen Pharmaceutical Company of Johnson & Johnson.

This symposium is not supported, endorsed, or accredited by the American College of Chest Physicians.

Agenda

5:00 PM – 5:50 PM  Interactive Presentation

5:50 PM -6:00 PM   Question & Answer Session/Closing Remarks

Dinner is On Us: Earn a $30 Uber Eats Credit

The symposium has gone virtual, but you can still dine with us. All participants who complete the following steps will be provided with a $30 Uber eats card compliments of Integrity Continuing Education:

  1. Pre-register for the symposium at www.integrityce.com/chest2021
  2. Complete the program pretest and participate in the live program. An email with more information will be sent within 1 week of the program.
  3. Complete the posttest and evaluation form.

Upon completion of all steps, a link will be provided to claim your $30 Uber Eats credit.